The Art and Science of Diagnosing and Managing Drug-induced Liver Injury in 2015 and Beyond

Clinical Gastroenterology and Hepatology

Volumn 13, Issue 12, 2015, Pages 2173-2189.e8

  Lewis, James H ^a  

^a GEORGETOWN UNIVERSITY HOSPITAL   (United States)

Author keywords

DILI; Drug induced Liver Injury; Hepatotoxicity

Indexed keywords

ACETYLCYSTEINE; ALANINE AMINOTRANSFERASE; ANTIBIOTIC AGENT; ANTILIPEMIC AGENT; BIOLOGICAL MARKER; CARNITINE; CENTRAL NERVOUS SYSTEM AGENTS; CYTOKERATIN 18; HERBACEOUS AGENT; HLA ANTIGEN; MICRORNA 122; PARACETAMOL; SILYMARIN; STEROID; URSODEOXYCHOLIC ACID;

ACUTE LIVER FAILURE; AGE DISTRIBUTION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN DIALYSIS; ANTIGEN EXPRESSION; CHRONIC LIVER DISEASE; DESENSITIZATION; DISEASE REGISTRY; DRUG EFFICACY; DRUG OVERDOSE; DRUG RECHALLENGE; DRUG SAFETY; FATALITY; GENETIC ASSOCIATION; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; INTERNET; LIVER ASSIST DEVICE; LIVER BIOPSY; LIVER METABOLISM; LIVER SUPPORT; LIVER TOXICITY; LIVER TRANSPLANTATION; METABOLOMICS; OUTCOME ASSESSMENT; PHARMACOGENETICS; PLASMAPHERESIS; POSTMARKETING SURVEILLANCE; PRACTICE GUIDELINE; PROGNOSIS; PROTEOMICS; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; SCORING SYSTEM; SEX DIFFERENCE; TOXIC HEPATITIS; BLOOD; CASE MANAGEMENT; DECISION SUPPORT SYSTEM; DRUG-INDUCED LIVER INJURY;

ALANINE TRANSAMINASE; BIOMARKERS; CASE MANAGEMENT; DECISION SUPPORT TECHNIQUES; DRUG-INDUCED LIVER INJURY; HUMANS; INTERNET;

EID: 84944388631     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2015.06.017     Document Type: Review

References (254)

1. Pyrosopoulos NT, ed. Drug hepatotoxicity. Clin Liver Dis 2013;17:507-786.
2. Chalasani N., Hayashi P.H. Slow but steady progress in a field with many knowledge gaps. Semin Liver Dis 2014, 34:113-114.
3. Drug-induced liver disease 2013, Elsevier/Academic Press, London. 3rd ed. N. Kaplowitz, L.D. DeLeve (Eds.).
4. Watkins P.B., Merz M. The clinical liver safety assessment best practices workshop: rationale, goals, accomplishments and the future. Drug Saf 2014, 37(Suppl 1):S1-S7.
5. Senior J, Watkins P, Avigan M, Pauls L. Drug-induced liver injury (DILI) conference XV: the importance of getting it right. Available at:. Accessed March 18-19, 2015. http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/ucm%20071471.htm.
6. Chalhoub W.M., Sliman K.D., Arumuganathan M., et al. Drug-induced liver injury: what was new in 2013?. Expert Opin Drug Metab Toxicol 2014, 10:1-22.
7. Zimmerman H.J. Hepatotoxocity: the adverse effects of drugs and other chemicals on the liver 1999, Lippincott, William & Wilkins, Philadelphia. 2nd ed.
8. Popper H., Rubin E., Cardiol D., et al. Drug-induced liver disease: a penalty for progress. Arch Intern Med 1965, 115:128-136.
9. Stricker B.H.C., Spoelstra P. Drug-induced hepatic injury 1985, Elsevier, Amsterdam.
10. Lewis J.H., Kleiner D.E. Hepatic injury due to drugs, herbal compounds, chemicals and toxins. MacSween's pathology of the liver 2012, 645-760. Churchill Livingstone, Edinburgh. 6th ed. A.D. Burt, B.C. Portmann, L.D. Ferrell (Eds.).
11. Navarro V.J., Senior J.R. Drug-related hepatotoxicity. N Engl J Med 2006, 354:731-739.
12. Luedde T., Kaplowitz N., Schwabe R.F. Cell death and cell death responses in liver disease: mechanisms and clinical relevance. Gastroenterology 2014, 147:765-783.
13. Tujios S., Fontana R.J. Mechanisms of drug-induced liver injury: from bedside to bench. Nat Rev Gastroenterol Hepatol 2011, 8:202-211.
14. Stephens C., Andrade R.J., Lucena M.I. Mechanisms of drug-induced liver injury. Curr Opin Allergy Clin Immunol 2014, 14:286-292.
15. Lee W.M. Drug-induced acute liver failure. Clin Liver Dis 2013, 17:575-586.
16. Reuben A., Koch D.G., Lee W.M., et al. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology 2010, 52:2065-2076.
17. Lewis J.H. Drug-induced liver injury throughout the drug development life cycle: where we have been, where we are now and where we are headed-perspectives of a clinical hepatologist. Pharmaceutical Medicine 2013, 27:165-191.
18. Avigan M.I. DILI and drug development: a regulatory perspective. Semin Liver Dis 2014, 34:215-226.
19. Regev A. Drug-induced liver injury and drug development: industry perspective. Semin Liver Dis 2014, 34:227-239.
20. Senior J.R. Evolution of the Food and Drug Administration approach to liver safety for new drugs: current status and challenges. Drug Saf 2014, 37(Suppl 1):S9-S17.
21. Wang B., Avorn J., Kesselheim A.S. Clinical and regulatory features of drugs not initially approved by the FDA. Clin Pharmacol Ther 2013, 94:670-677.
22. Stine J.G., Lewis J.H. Drug-induced liver injury: a summary of recent advances. Expert Opin Drug Metab Toxicol 2011, 7:1-16.
23. Temple R. Hy's Law: predicting serious hepatotoxicity. Pharmacoepidemiol Drug Saf 2006, 15:241-243.
24. Przybylak K., Cronin M. In silico models for drug-induced liver injury: current status. Expert Opin Drug Metab Toxicol 2012, 201-217.
25. Stepan A., Walker D., Bauman J., et al. Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States. Chem Res Toxicol 2011, 24:1345-1410.
26. Zhang M., Chen M., Tong W. Is toxicogenomics a more reliable and sensitive biomarker than conventional indicators from rats to predict drug-induced injury in humans. Chem Res Toxicol 2012, 25:122-129.
27. Liu Z., Shi Q., Ding D., et al. Translating clinical findings into knowledge in drug safety evaluation: Drug-Induced Liver Injury Prediction System (DILIps). PLoS Comput Biol 2011, 12:e1002310.
28. Cheng F., Theodorescu D., Shulman I., et al. In vitro transcriptomic prediction of hepatotoxicity for early drug discovery. J Theoret Biol 2011, 290:27-36.
29. Amacher D.E. The primary role of hepatic metabolism in idiosyncratic drug-induced liver injury. Expert Opin Drug Metab Toxicol 2012, 8:335-347.
30. Xu J., Dunn M., Smith A., et al. Assessment of hepatotoxicity potential of drug candidate molecules including kinase inhibitors by hepatocyte imaging assay technology and bile flux imaging assay technology. Methods Mol Biol 2012, 795:83-107.
31. Woodhead J.L., Yang K., Siler S.Q., et al. Mechanistic modeling reveals the critical knowledge gaps in bile acid-mediated DILI. CPT Pharmacometrics Syst Pharmacol 2014, 3:e123.
32. Guo T, Gelperin K, Senior JR. A tool to help you decide (detect potentially serious liver injury). Available at:. Accessed July 18, 2015. http://www.fda.gov/downloads/Drugs/ScienceResearch/ResearchAreas/ucm076777.pdf.
33. Chen M., Borlak J., Tong W. High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury. Hepatology 2013, 58:388-396.
34. Chen M., Tung C.W., Shi Q., et al. A testing strategy to predict risk for drug-induced liver injury in humans using high-content screen assays and the 'rule-of-two' model. Arch Toxicol 2014, 88:1439-1449.
35. Brinker A.D., Lyndly J., Tonning J., et al. Profiling cumulative proportional reporting ratios of drug-induced liver injury in the FDA Adverse Event Reporting System (FAERS) database. Drug Saf 2013, 36:1169-1178.
36. Behrman R.E., Benner J.S., Brown J.S., et al. Developing the Sentinel System: a national resource for evidence development. N Engl J Med 2011, 364:498-499.
37. Chen M., Zhang J., Wang Y., et al. The Liver Toxicity Knowledge Base: a systems approach to a complex end point. Clin Pharmacol Ther 2013, 93:409-412.
38. Andrews S., Holden R. Characteristics and management of immune-related adverse effects associated with a new immunotherapy for metastatic melanoma. Cancer Manag Res 2012, 4:299-307.
39. Kleiner D.E., Berman D. Pathologic changes in ipilimumab-related hepatitis in patients with metastatic melanoma. Dig Dis Sci 2012, 57:2233-2240.
40. Felser A., Blum K., Lindinger P.W., et al. Mechanisms of hepatocellular toxicity associated with dronedarone: a comparison to amiodarone. Toxicol Sci 2013, 131:480-490.
41. Watkins P.B., Lewis J.H., Kaplowitz N., et al. Clinical pattern of tolvaptan-associated liver injury in subjects with autosomal dominant polycystic kidney disease: analysis of clinical trials database. Drug Saf 19 July 2015, (Epub ahead of print).
42. Brinker A.D., Wassel R.T., Lyndly J., et al. Telithromycin-associated hepatotoxicity: clinical spectrum and causality assessment of 42 cases. Hepatology 2009, 49:250-257.
43. Vuppalanchi R., Hayashi P.H., Chalasani N., et al. Duloxetine hepatotoxicity: a case-series from the drug-induced liver injury network. Aliment Pharmacol Ther 2010, 32:1174-1183.
44. Orman E.S., Conjeevaram H.S., Vuppalanchi R., et al. Clinical and histopathologic features of fluoroquinolone-induced liver injury. Clin Gastroenterol Hepatol 2011, 9:517-523.
45. Russo M.W., Hoofnagle J.H., Gu J., et al. Spectrum of statin hepatotoxicity: experience of the drug-induced liver injury network. Hepatology 2014, 60:679-686.
46. Martinez M.A., Vuppalanchi R., Fontana R.J., et al. Clinical and histologic features of azithromycin-induced liver injury. Clin Gastroenterol Hepatol 2015, 13:369-376.
47. Iacovelli R., Palazzo A., Procopio G., et al. Incidence and relative risk of hepatic toxicity in patients treated with antiangiogenic tyrosine kinase inhibitors for malignancy. Br J Clin Pharmacol 2014, 77:929-938.
48. Aleo M.D., Luo Y., Swiss R., et al. Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump. Hepatology 2014, 60:1015-1022.
49. Boelsterli U.A., Lee P.K. Mechanisms of isoniazid-induced idiosyncratic liver injury: emerging role of mitochondrial stress. J Gastroenterol Hepatol 2014, 29:678-687.
50. Ribeiro M.P., Santos A.E., Custodio J.B. Mitochondria: the gateway for tamoxifen-induced liver injury. Toxicology 2014, 323:10-18.
51. Webb G.J., Adams D.H. Modeling idiosyncrasy: a novel animal model of drug-induced liver injury. Hepatology 2015, 61:1124-1126.
52. Metushi I.G., Cai P., Zhu X., et al. A fresh look at the mechanism of isoniazid-induced hepatotoxicity. Clin Pharmacol Ther 2011, 89:911-914.
53. Fontana R.J. Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives. Gastroenterology 2014, 146:914-928.
54. Daly A.K., Day C.P. Genetic association studies in drug-induced liver injury. Drug Metab Rev 2012, 44:116-126.
55. Urban T.J., Daly A.K., Aithal G.P. Genetic basis of drug-induced liver injury: present and future. Semin Liver Dis 2014, 34:123-133.
56. Chen R., Zhang Y., Tang S., et al. The association between HLA-DQB1 polymorphism and antituberculosis drug-induced liver injury: a case-control study. J Clin Pharm Ther 2015, 40:110-115.
57. Visschers R.G., Luyer M.D., Schaap F.G., et al. The gut-liver axis. Curr Opin Clin Nutr Metab Care 2013, 16:576-581.
58. Possamai L.A., McPhail M.J., Khamri W., et al. The role of intestinal microbiota in murine models of acetaminophen-induced hepatotoxoicity. Liver Int 2015, 35:764-773.
59. Hawkins M.T., Lewis J.H. Latest advances in predicting DILI in human subjects: focus on biomarkers. Expert Opin Drug Metab Toxicol 2012, 8:1521-1530.
60. Bell L.N., Vuppalanchi R., Watkins P.B., et al. Serum proteomic profiling in patients with drug-induced liver injury. Aliment Pharmacol Ther 2012, 35:600-612.
61. Steuerwald N.M., Foureau D.M., Norton H.J., et al. Profiles of serum cytokines in acute drug-induced liver injury and their prognostic significance. PLoS One 2013, 8:e81974.
62. Welch M.A., Kock K., Urban T.J., et al. Towards predicting drug-induced liver injury (DILI): parallel computational approaches to identify MRP4 and BSEP inhibitors. Drug Metab Dispos 2015, 43:725-734.
63. Rockey D.C., Seeff L.B., Rochon J., et al. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology 2010, 51:2117-2126.
64. Lewis J.H. Causality assessment: which is best-expert opinion or RUCAM?. Clinical Liver Dis 2014, 4:4-8.
65. Regev A., Seeff L.B., Merz M., et al. Causality assessment for suspected DILI during clinical phases of drug development. Drug Saf 2014, 37(Suppl 1):S47-S56.
66. Teo Y.L., Ho H.K., Chan A. Formation of reactive metabolites and management of tyrosine kinase inhibitor-induced hepatotoxicity: a literature review. Expert Opin Drug Metab Toxicol 2014, 15:1-12.
67. Momen-Heravi F., Bala S., Bukong T., et al. Exosome-mediated delivery of functionally active miRNA-155 inhibitor to macrophages. Nanomedicine 2014, 10:1517-1527.
68. Lexmond W.S., Van Dael C.M., Scheenstra R., et al. Experience with molecular adsorbent recirculating system treatment in 20 children listed for high-urgency liver transplantation. Liver Transpl 2015, 21:369-380.
69. Liu C.T., Chen T.H., Cheng C.Y. Successful treatment of drug-induced acute liver failure with high-volume plasma exchange. J Clin Apheresis 2013, 28:430-434.
70. Wree A., Dechene A., Herzer K., et al. Steroid and ursodeozycholic acid combination therapy in severe drug-induced liver injury. Digestion 2011, 84:54-59.
71. Singh S., Hynan L.S., Lee W.M., et al. Improvements in hepatic serological biomarkers are associated with clinical benefits of intravenous N-acetylcysteine in early stage non-acetaminophen acute liver failure. Dig Dis Sci 2013, 58:1397-1402.
72. Squires R.H., Dhawan A., Alonso E., et al. Intravenous N-acetylcysteine in pediatric patients with nonacetaminophen acute liver failure: a placebo-controlled clinical trial. Hepatology 2013, 57:1542-1549.
73. Chalasani N.P., Hayashi P.H., Bonkovsky H.L., et al. ACG clinical guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol 2014, 109:950-966.
74. Hoofnagle J.H. Drug-induced liver injury network (DILIN). Hepatology 2004, 40:773.
75. Fontana R.J., Watkins P.B., Bonkovsky H.L., et al. Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf 2009, 32:55-68.
76. Chalasani N., Bonkovsky H.L., Fontana R.J., et al. Drug-induced liver in the USA: a report of 899 instances assessed prospectively. Gastroenterology 2015, 148:1340-1352.
77. Navarro V.J., Barnhart H., Bonkovsky H.L., et al. Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network. Hepatology 2014, 60:1399-1408.
78. Andrade R.J., Lucena M.I., Fernandez M.C., et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005, 129:512-521.
79. Bjornsson E., Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology 2005, 42:481-489.
80. Devarbhavi H., Dierkhising R., Kremers W.K., et al. Single-center experience with drug-induced liver injury from India: causes, outcome, prognosis, and predictors of mortality. Am J Gastroenterol 2010, 105:2396-2404.
81. Sistanizad M., Peterson G.M. Drug-induced liver injury in the Australian setting. J Clin Pharmacol Ther 2013, 38:115-120.
82. Bjornsson E.S., Bergmann O.M., Bjornsson H.K., et al. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology 2013, 144:1419-1425.
83. Suk K.T., Kim D.J., Kim C.H., et al. A prospective nationwide study of drug-induced liver injury in Korea. Am J Gastroenterol 2012, 107:1380-1387.
84. Petronijevic M., Ilic K. Associations of gender and age with the reporting of drug-induced hepatic failure: data from VigiBase™. J Clin Pharmacol 2013, 53:435-443.
85. Hoofnagle J.H., Serrano J., Knoben J.E., et al. LiverTox: a website on drug-induced liver injury. Hepatology 2013, 57:873-874.
86. Adams D.H., Ju C., Ramaiah S.K., et al. Mechanisms of immune-mediated liver injury. Toxicol Sci 2010, 115:307-321.
87. Uetrecht J., Naisbitt D.J. Idiosyncratic adverse drug reactions: current concepts. Pharmacol Rev 2013, 65:779-808.
88. Zhang X., Liu F., Chen X., et al. Involvement of the immune system in idiosyncratic drug reactions. Drug Metab Pharmacokinet 2011, 26:47-59.
89. Kenna J.G. Current concepts in drug-induced bile salt export pump (BSEP) interference. Curr Protoc Toxicol 2014, 61:23.7.1-23.7.15.
90. Welch M.A., Kock K., Urban T.J., et al. Toward predicting drug-induced liver injury: parallel computational approaches to identify multidrug resistance protein 4 and bile salt export pump inhibitors. Drug Metab Dispos 2015, 43:725-734.
91. Au J.S., Navarro V.J., Rossi S. Review article: drug-induced liver injury-its pathophysiology and evolving diagnostic tools. Aliment Pharmacol Ther 2011, 34:11-20.
92. Buness A., Roth A., Hermann A., et al. Identification of metabolites, clinical chemistry markers and transcripts associated with hepatotoxicity. PLoS One 2014, 16;9:e97249.
93. Eun J.W., Bae H.J., Shen Q., et al. Characteristic molecular and proteomic signatures of drug-induced liver injury in a rat model. J Appl Toxicol 2015, 35:152-164.
94. Mattes W., Davis K., Fabian E., et al. Detection of hepatotoxicity potential with metabolite profiling (metabolomics) of rat plasma. Toxicol Lett 2014, 230:467-478.
95. Chen M., Bisgin H., Tong L., et al. Toward predictive models for drug-induced liver injury in humans: are we there yet?. Biomarkers Med 2014, 8:201-213.
96. Knudsen T.B., Keller D.A., Sander M., et al. FutureTox II: in vitro data and in silico models for predictive toxicology. Toxicol Sci 2015, 143:256-267.
97. Grove J.I., Aithal G.P. Human leukocyte antigen genetic risk factors of drug-induced liver toxicology. Expert Opin Drug Metab Toxicol 2014, 10:1-15.
98. Matsumoto T., Ohno M., Azuma J. Future of pharmacogenetics-based therapy for tuberculosis. Pharmacogenomics 2014, 15:601-607.
99. Urban T.J., Shen Y., Stolz A., et al. Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs. Pharmacogenet Genomics 2012, 22:784-795.
100. Alfirevic A., Pirmohamed M. Predictive genetic testing for drug-induced liver injury: considerations of clinical utility. Clin Pharmacol Ther 2012, 92:376-380.
101. Overby C.L., Hripcsak G., Shen Y. Estimating heritability of drug-induced liver injury from common variants and implications for future study designs. Scientific Rep 2014, 4:5762.
102. Tang S.W., Lv X.Z., Chen R., et al. Lack of association between genetic polymorphisms of CYP3A4, CYP2C9 and CYP2C19 and antituberculosis drug-induced liver injury in a community-based Chinese population. Clin Exp Pharmacol Physiol 2013, 40:326-332.
103. Chen M., Suzuki A., Borlak J., et al. Drug-induced liver injury: interactions between drug properties and host factors. J Hepatol. 2015, 63:503-514.
104. Aithal G.P. Pharmacgenetic testing in idiosyncratic drug-induced liver injury: current role in clinical practice. Liver Int 2015, 35:1801-1807.
105. Avigan M.I., Bjornsson E.S., Pasanen M., et al. Liver safety assessment: required data elements and best practices for data collection and standardization in clinical trials. Drug Saf 2014, 37(Suppl 1):S19-S31.
106. Kullak-Ublick G.A., Merz M., Griffel L., et al. Liver safety assessment in special populations (hepatitis B, C and oncology trials). Drug Saf 2014, 37(Suppl 1):S57-S62.
107. Goodsaid F.M., Frueh F.W., Mattes W. The Predictive Safety Testing Consortium: a synthesis of the goals, challenges and accomplishments of the Critical Path. Drug Disc Today Technol 2007, 4:47-50.
108. The International Serious Adverse Event Consortium (iSAEC). Available at:. Accessed July 18, 2015. http://www.saeconsortium.org.
109. The DILI-sim initiative and DILIsym® software. Available at:. Accessed July 18, 2015. http://dilisym.com.
110. Weiler S., Merz M., Kullak-Ublick G.A. Drug-induced liver injury: the dawn of biomarkers?. F1000Prime Rep 2015, 7:34.
111. Aithal G.P., Rawlins M.D., Day C.P. Accuracy of hepatic adverse drug reaction reporting in one English health region. BMJ 1999, 319:1541.
112. Sgro C., Clinard F., Ouazir K., et al. Incidence of drug-induced injuries: a French population-based study. Hepatology 2002, 36:451-455.
113. Meier Y., Cavallaro M., Roos M., et al. Incidence of drug-induced liver injury in medical in-patients. Eur J Clin Pharmacol 2005, 61:135-143.
114. Bjornsson E.S. Epidemiology and risk factors for idiosyncratic drug-induced liver injury. Semin Liver Dis 2014, 34:115-122.
115. Vuppalanchi R., Liangpunsakul S., Chalasani N. Etiology of new-onset jaundice: how often is it caused by idiosyncratic drug-induced liver injury in the United States?. Am J Gastroenterol 2007, 102:558-562.
116. Carey E.J., Vargas H.E., Douglas D.D., et al. Inpatient admissions for drug-induced liver injury: results from a single center. Dig Dis Sci 2008, 53:1977-1982.
117. Galan M.V., Potts J.A., Silverman A.L., et al. The burden of acute nonfulminant drug-induced hepatitis in a United States tertiary referral center. J Clin Gastroenterol 2005, 39:64-67.
118. Wysowski D.K., Swartz L. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions. Arch Intern Med 2005, 165:1363-1369.
119. Lucena M.I., Andrade R.J., Rodrigo L., et al. Trovafloxacin-induced acute hepatitis. Clin Infect Dis 2000, 30:400-401.
120. Fontana R.J., McCashland T.M., Benner K.G., et al. Acute liver failure associated with prolonged use of bromfenac leading to liver transplantation: the Acute Liver Failure Study Group. Liver Transpl Surg 1999, 5:480-484.
121. Graham D.J., Green L., Senior J.R., et al. Troglitazone-induced liver failure: a case study. Am J Med 2003, 114:299-306.
122. Goldkind L., Laine L. A systematic review of NSAIDs withdrawn from the market due to hepatotoxicity: lessons learned from the bromfenac experience. Pharmacoepidemiol Drug Saf 2006, 15:213-220.
123. Lee W.M., Larrey D., Olsson R., et al. Hepatic findings in long-term clinical trials of ximelagatran. Drug Saf 2005, 28:351-370.
124. Lewis J.H. 'Hy's law', 'the Rezulin Rule' and other predictors of severe drug-induced hepatotoxicity: putting risk-benefit into perspective. Pharmacoepidemiol Drug Saf 2006, 15:221-229.
125. Singer J.B., Lewitzky S., Leroy E., et al. A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury. Nat Genet 2010, 42:711-1471.
126. Navarro V.J., Lucena M.I. Hepatotoxicity induced by herbal and dietary supplements. Semin Liver Dis 2014, 34:172-193.
127. Navarro V.J., Bonkovsky H.L., Hwang S.I., et al. Catechins in dietary supplements and hepatotoxicity. Dig Dis Sci 2013, 58:2682-2690.
128. Seeff L.B., Bonkovsky H.L., Navarro V.J., et al. Herbal products and the liver: review of adverse effects and mechanisms. Gastroenterology 2015, 148:517-532.
129. Teschke R., Wolff A., Frenzel C., et al. Herbal hepatotoxicity: a tabular compilation of reported cases. Liver Int 2012, 32:1543-1556.
130. Teschke R., Wolff A., Frenzel C., et al. Review article: herbal hepatotoxicity-an update on traditional Chinese medicine preparations. Aliment Pharmacol Ther 2014, 40:32-50.
131. Elinav E., Pinsker G., Safadi R., et al. Association between consumption of Herbalife nutritional supplements and acute hepatotoxicity. J Hepatol 2007, 47:514-520.
132. Roytman M.M., Porzgen P., Lee C.L., et al. Outbreak of severe hepatitis linked to weight-loss supplement OxyELITE Pro. Am J Gastroenterol 2014, 109:1296-1298.
133. Zhao C.Q., Zhou Y., Ping J., et al. Traditional Chinese medicine for treatment of liver diseases: progress, challenges and opportunities. J Integr Med 2014, 12:401-408.
134. Oh S.J., Cho J.H., Son C.G. Systematic review of the incidence of herbal drug-induced liver injury in Korea. J Ethnopharmacol 2015, 159:253-256.
135. Danan G., Benichou C. Causality assessment of adverse reactions to drugs: I-a novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993, 46:1323-1330.
136. Senior J.R. Monitoring for hepatotoxicity: what is the predictive value of liver 'function' tests?. Clin Pharmacol Ther 2009, 85:331-334.
137. Senior J.R. How can "Hy's law" help the clinician?. Pharmacoepidemiol Drug Saf 2006, 15:235-239.
138. Galvin Z., McDonough A., Ryan J., et al. Blood alanine aminotransferase levels >1000 IU/L: causes and outcomes. Clin Med 2015, 15:244-247.
139. Lewis J.H. Drug-induced liver disease. Med Clin North Am 2000, 84:1275-1311.
140. Ishak K.G., Zimmerman H.J. Morphologic spectrum of drug-induced hepatic disease. Gastroenterol Clin North Am 1995, 24:759-786.
141. Kleiner D.E., Chalasani N.P., Lee W.M., et al. Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations. Hepatology 2014, 59:661-670.
142. Watkins P.B. Biomarkers for the diagnosis and management of drug-induced liver injury. Semin Liver Dis 2009, 29:393-399.
143. Zimmerman H.J., Ishak K.G. General aspects of drug-induced liver disease. Gastroenterol Clin North Am 1995, 24:739-757.
144. Davern T.J., Chalasani N., Fontana R.J., et al. Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury. Gastroenterology 2011, 141:1665-1672.
145. Kaplowitz N. Causality assessment versus guilt-by-association in drug hepatotoxicity. Hepatology 2001, 33:308-310.
146. Aithal G.P., Watkins P.B., Andrade R.J., et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther 2011, 89:806-815.
147. Benichou C., Danan G., Flahault A. Causality assessment of adverse reactions to drugs: II-an original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol 1993, 46:1331-1336.
148. Shapiro M.A., Lewis J.H. Causality assessment of drug-induced hepatotoxicity: promises and pitfalls. Clin Liver Dis 2007, 11:477-505.
149. Garcia-Cortes M., Stephens C., Lucena M.I., et al. Causality assessment methods in drug induced liver injury: strengths and weaknesses. J Hepatol 2011, 55:683-691.
150. Rockey D.C., Seeff L.B., Rochon J., et al. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf Causality Assessment Method. Hepatology 2010, 51:2117-2126.
151. Senior J.R. New biomarkers for drug-induced liver injury: are they really better? what do they diagnose?. Liver Int 2014, 34:325-327.
152. Agrawal V.K., McHutchison J.G., Hoofnagle J.H. Important elements for the diagnosis of drug-induced liver injury. Clin Gastroenterol Hepatol 2010, 8:463-470. for the Drug-Induced Liver Injury Network.
153. Ulcickas Yood M., Bortolini M., Casso D., et al. Incidence of liver injury among cancer patients receiving chemotherapy in an integrated health system. Pharmacoepidemiology Drug Saf 2015, 24:427-434.
154. Ambrosy A.P., Vaduganathan M., Huffman M.D., et al. Clinical course and predictive value of liver function tests in patients hospitalized for worsening heart failure with reduced ejection fraction: an analysis of the EVEREST trial. Eur J Heart Fail 2012, 14:302-311.
155. Teschke R., Frenzel C., Schulze J., et al. Herbal hepatotoxicity: challenges and pitfalls of causality assessment methods. World J Gastroenterol 2013, 19:2864-2882.
156. Hayashi P.H., Barnhart H.X., Fontana R.J., et al. Reliability of causality assessment for drug, herbal and dietary supplement hepatotoxicity in the Drug-Induced Liver Injury Network (DILIN). Liver Int 2015, 35:1623-1632.
157. Vuppalanchi R., Navarro V., Vega M., et al. Herbal dietary supplement associated hepatotoxicity: an upcoming workshop and need for research. Gastroenterology 2015, 148:480-482.
158. Squires R.H., Shneider B.L., Bucuvalas J., et al. Acute liver failure in children: the first 348 patients in the Pediatric Acute Liver Failure Study Group. J Pediatr 2006, 148:652-658.
159. Molleston J.P., Fontana R.J., Lopez M.J., et al. Characteristics of idiosyncratic drug-induced liver injury in children: results from the DILIN prospective study. J Pediatr Gastroenterol Nutr 2011, 53:182-189.
160. Hunt C.M., Yuen N.A., Stirnadel-Farrant H.A., et al. Age-related differences in reporting of drug-associated liver injury: data-mining of WHO Safety Report Database. Regul Toxicol Pharmacol 2014, 70:519-526.
161. Stine J.G., Sateesh P., Lewis J.H. Drug-induced liver injury in the elderly. Curr Gastroenterol Rep 2013, 15:299.
162. Lucena M.I., Andrade R.J., Kaplowitz N., et al. Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex. Hepatology 2009, 49:2001-2009.
163. Woodhouse K., Wynne H.A. Age-related changes in hepatic function: implications in drug therapy. Drug Aging 1992, 2:243-255.
164. Corsini A., Bortolini M. Drug-induced liver injury: the role of drug metabolism and transport. J Clin Pharmacol 2013, 53:463-474.
165. Vuppalanchi R., Gotur R., Reddy K.R., et al. Relationship between characteristics of medications and drug-induced liver disease phenotype and outcome. Clin Gastroenterol Hepatol 2014, 12:1550-1555.
166. Lewis J.H. Drug-induced liver injury, dosage, and drug disposition: is idiosyncrasy really unpredictable?. Clin Gastroenterol Hepatol 2014, 12:1556-1561.
167. Lammert C., Einarsson S., Saha C., et al. Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals. Hepatology 2008, 47:2003-2009.
168. Lammert C., Bjornsson E., Niklasson A., et al. Oral medications with significant hepatic metabolism at higher risk for hepatic adverse effects. Hepatology 2010, 51:615-620.
169. Yu K., Geng X., Chen M., et al. High daily dose and being a substrate of cytochrome P450 enzymes are two important predictors of drug-induced liver injury. Drug Metab Dispo 2014, 42:744-750.
170. Starkey Lewis P.J., Dear J., Platt V., et al. Circulating microRNAs as potential markers of human drug-induced liver injury. Hepatology 2011, 54:1767-1776.
171. Antoine D.J., Dear J.W., Lewis P.S., et al. Mechanistic biomarkers provide early and sensitive detection of acetaminophen-induced acute liver injury at first presentation to hospital. Hepatology 2013, 58:777-787.
172. Roderburg C., Benz F., Vargas Cardenas D., et al. Elevated miR-122 serum levels are an independent marker of liver injury in inflammatory diseases. Liver Int 2015, 35:1172-1184.
173. Yang M., Antoine D.J., Weemhoff J.L., et al. Biomarkers distinguish apoptotic and necrotic cell death during hepatic ischemia/reperfusion injury in mice. Liver Transpl 2014, 20:1372-1382.
174. Yang X., Salminen W.F., Shi Q., et al. Potential of extracellular microRNAs as biomarkers of acetaminophen toxicity in children. Toxicol Appl Pharmacol 2015, 284:180-187.
175. Dear J.W., Antoine D.J. Stratification of paracetamol overdose patients using new toxicity biomarkers: current candidates and future challenges. Expert Rev Clin Pharmacol 2014, 7:181-189.
176. Phillips E., Mallal S. Successful translation of pharmacogenetics into the clinic: the abacavir example. Mol Diagn Ther 2009, 13:1-9.
177. Ng C.S., Hasnat A., Al Maruf A., et al. N-acetyltransferase 2 (NAT2) genotype as a risk factor for development of drug-induced liver injury relating to antituberculosis drug treatment in a mixed-ethnicity patient group. Eur J Clin Pharmacol 2014, 70:1079-1086.
178. Gupta N.K., Lewis J.H. Review article: the use of potentially hepatotoxic drugs in patients with liver disease. Aliment Pharmacol Ther 2008, 28:1021-1041.
179. Alcorn N., Saunders S., Madhok R. Benefit-risk assessment of leflunomide: an appraisal of leflunomide in rheumatoid arthritis 10 years after licensing. Drug Saf 2009, 32:1123-1134.
180. Lee S.-W., Park H.-J., Kim B.K., et al. Leflunomide increases the risk of silent liver fibrosis in patients with rheumatoid arthritis receiving methotrexate. Arthritis Res Ther 2012, 14:R232.
181. Bjornsson E.S., Jacobsen E.I., Einarsdottir R., et al. Discrepancies in liver disease labeling in the package inserts of commonly prescribed medications. Gastroenterology 2015, 148:269-273.
182. Delco F., Tchambaz L., Schlienger R., et al. Dose adjustment in patients with liver disease. Drug Saf 2005, 28:529-545.
183. Lewis J.H., Stine J.G. Review article: prescribing medications in patients with cirrhosis-a practical guide. Aliment Pharmacol Ther 2013, 37:1132-1156.
184. Lucena M.I., Andrade R.J., Tognoni G., et al. Drug use for non-hepatic conditions in patients with liver cirrhosis. Eur J Clin Pharmacol 2003, 59:71-76.
185. Rossi S., Assis D.N., Awsare M., et al. Use of over-the-counter analgesics in patients with chronic liver disease: physicians' recommendations. Drug Saf 2008, 31:261-270.
186. Nguyen D., Banerjee N., Abdelaziz D., et al. Trainees' attitudes and preferences toward the use of over the counter analgesics in patients with chronic liver disease. Adv Pharmacoepidemiol Drug Saf 2014, 3:1000167.
187. Watkins P.B., Kaplowitz N., Slattery J.T., et al. Aminotransferase elevations in healthy subjects receiving 4 grams of acetaminophen daily: a randomized controlled trial. JAMA 2006, 296:87-93.
188. Lewis J.H. Clinical perspective: statins and the liver-harmful or helpful?. Dig Dis Sci 2012, 57:1754-1763.
189. Vuppalanchi R., Teal E., Chalasani N. Patients with elevated baseline liver enzymes do not have a higher frequency of hepatotoxicity from lovastatin than those with normal baseline liver enzymes. Am J Med Sci 2005, 329:62-65.
190. Lewis J.H., Mortensen M.E., Zweig S., et al. Efficacy and safety of high-dose pravastatin in hypercholesteroloemic patients with well-compensated chronic liver disease: results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Hepatology 2007, 46:1453-1463.
191. Kumar S., Grace N.D., Qamar A.A. Statin use in cirrhosis: a retrospective cohort study. Dig Dis Sci 2014, 59:1958-1965.
192. Lewis J.H. Prescribing a statin to a cirrhotic patient to reduce hepatic decompensation and improve survival: impossible you say?. Dig Dis Sci 2014, 59:1684-1687.
193. Singh S., Singh P.P., Singh A.G., et al. Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis. Gastroenterology 2013, 144:323-332.
194. Vallianou N.G., Kostantinou A., Kougias M., et al. Statins and cancer. Anticancer Agents Med Chem 2014, 14:706-712.
195. Reuben A. Hy's law. Hepatology 2004, 39:574-578.
196. Kaplowitz N. Rules and laws of drug hepatotoxicity. Pharmacoepidemiol Drug Saf 2006, 15:231-233.
197. Senior J.R. Drug hepatotoxicity from a regulatory perspective. Clin Liver Dis 2007, 11:507-524.
198. Regev A., Bjornsson E.S. Drug-induced liver injury: morbidity, mortality and Hy's Law. Gastroenterology 2014, 147:20-24.
199. Drug-induced liver injury: premarketing clinical evaluation July 2009, Guidance for industry, Food and Drug Administration, Silver Spring, MD, Available at: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm174090.pdf. Accessed July 18, 2015.
200. Fontana R.J., Hayashi P.H., Gu J., et al. Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset. Gastroenterology 2014, 147:96-108.
201. Devarbhavi H., Singh R., Patil M., et al. Outcome and determinants of mortality in 269 patients with combination anti-tuberculosis drug-induced liver injury. J Gastroenterol Hepatol 2013, 28:161-167.
202. Parks D., Lin X., Painter J.L., et al. A proposed modification to Hy's law and Edish criteria in oncology clinical trials using appregated historical data. Pharmacoepidemiol Drug Saf 2013, 22:571-578.
203. Robles-Diaz M., Lucena M.I., Kaplowitz N., et al. Use of Hy's Law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury. Gastroenterology 2014, 147:109-118.
204. Lewis J.H., Zimmerman J.H. Drug- and chemical-induced cholestasis. Clin Liver Dis 1999, 3:433-464.
205. Marino G., Zimmerman H.J., Lewis J.H. Management of drug-induced liver disease. Curr Gastroenterol Rep 2001, 3:38-48.
206. Aithal P.G., Day C.P. The natural history of histologically proved drug induced liver disease. Gut 1999, 44:731-735.
207. Desmet V. Vanishing bile duct syndrome in drug-induced liver disease. J Hepatol 1988, 7:193-199.
208. Degott C., Feldman G., Larrey D., et al. Drug-induced prolonged cholestasis in adults: a histological semiquantitative study demonstrating progressive ductopenia. Hepatology 1992, 15:244-251.
209. Mohi-ud-din R., Lewis J.H. Drug- and chemical-induced cholestasis. Clin Liver Dis 2004, 8:95-132.
210. Bjornsson E., Talwalker J., Treeprasertsuk S., et al. Drug-induced autoimmune hepatitis: clinical characteristics and prognosis. Hepatology 2010, 51:2040-2048.
211. Licata A., Maida M., Cabibi D., et al. Clinical features and outcomes of patients with drug-induced autoimmune hepatitis: a retrospective cohort study. Dig Liver Dis 2014, 46:1116-1120.
212. Suzuki A., Brunt E.M., Kleiner D.E., et al. The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. Hepatology 2011, 54:931-939.
213. Fontana R.J., Hayashi P.H., Watkins P.B., et al. Cholestatic drug reactions are more likely to cause persistent liver injury and impaired quality of life during prolonged follow-up: results from the DILIN Prospective study 2014, AASLD, Boston, abstract #1067.
214. Björnsson E., Davidsdottir L. The long-term follow-up after idiosyncratic drug-induced liver injury with jaundice. J Hepatol 2009, 50:511-517.
215. Graham D., Drinkard C., Shatin D., et al. Liver enzyme monitoring in patients treated with troglitazone. JAMA 2001, 286:831-833.
216. Blanchette C.M., Nunes A.P., Lin N.D., et al. Adherence to risk evaluation and mitigation strategies (REMS) requirements for monthly testing of liver function. Drugs Context 2015, 10:4.
217. Markova S.M., DeMarco T., Bendjilali N., et al. Association of CYP2C9*2 with bosentan-induced liver injury. Clin Pharmacol Ther 2013, 94:678-686.
218. Seyfarth H.J., Favreau N., Tennert C., et al. Genetic susceptibility to hepatoxicity due to bosentan treatment in pulmonary hypertension. Ann Hepatol 2014, 13:803-809.
219. Watkins P.B. Managing the risk of drug-induced liver injury. Clin Pharmacol Ther 2013, 94:629-631.
220. Roustit M., Fonrose X., Montani D., et al. CYP2C9, SLCO1B1, SLCO1B3, and ABCB11 polymorphisms in patients with bosentan-induced liver toxicity. Clin Pharmacol Ther 2014, 95:583-585.
221. Pollock N.R., Colby D., Rolland J.P. A point-of-care paper-based fingerstick transaminase test: toward low-cost "lab-on-a-chip" technology for the developing world. Clin Gastroenterol Hepatol 2013, 11:478-482.
222. Pollock N.R., McGray S., Colby D.J., et al. Field evaluation of a prototype paper-based point-of-care fingerstick transaminase test. PLoS One 2013, 8:e75616.
223. Saukkonen J.J., Cohn D.L., Jasmer R.M., et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006, 174:935-952.
224. Hayashi P.H., Fontana R.J., Chalasani N.P., et al. Under-reporting and poor adherence to monitoring guidelines for severe cases of isoniazid hepatotoxicity. Clin Gastroenterol Hepatol 2015.
225. Nglazi M.D., Bekker L.G., Wood R., et al. Mobile phone text messaging for promoting adherence to anti-tuberculosis treatment: a systematic review. BMC Infect Dis 2013, 13:566.
226. Leaver H., Keng Lim T., Thompson P., et al. Compliance to recommended liver function monitoring in patients on statin therapy. Cardiovasc Ther 2009, 27:96-100.
227. FDA Drug Safety Communication. Important safety label changes to cholesterol-lowering statin drugs. February 28, 2012. Available at:. Accessed July 18, 2015. http://www.fda.gov/Drugs/DrugSafety/ucm293101.htm.
228. Andrade R.J., Robles M., Lucena M.I. Rechallenge in drug-induced liver injury: the attractive hazard. Expert Opin Drug Saf 2009, 8:709-714.
229. Papay J.I., Clines D., Rafi R., et al. Drug-induced liver injury following positive drug rechallenge. Regul Toxicol Pharmacol 2009, 54:84-90.
230. Hunt C.M., Papay J.I., Rich D.S., et al. The evaluation of drug rechallenge: the casopitant Phase III program. Regul Toxicol Pharmacol 2010, 58:539-543.
231. Hunt C.M. Mitochondrial and immunoallergic injury increase risk of positive drug rechallenge after drug-induced liver injury: a systematic review. Hepatology 2010, 52:2216-2222.
232. Sharma S.K., Singla R., Sarda P., et al. Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity. Clin Infect Dis 2010, 50:833-839.
233. Saukkonen J. Challenges in reintroducing tuberculosis medications after hepatotoxicity. Clin Infect Dis 2010, 50:840-842.
234. Thongraung W., Lertphongpiroon W., Pungrassami P., et al. Physicians' practices regarding management of antituberculosis drug-induced hepatotoxicity. Southeast Asian J Trop Med Public Health 2012, 43:724-734.
235. Thong B.Y., Chia F.L., Tan S.C., et al. A retrospective study on sequential desensitization-rechallenge for antituberculosis drug allergy. Asia Pac Allergy 2014, 4:156-163.
236. Charles E.C., Olson K.L., Sandhoff B.G., et al. Evaluation of cases of severe statin-related transaminitis within a large health maintainance organization. Am J Med 2005, 118:618-624.
237. Lebovitz H.E. Differentiating members of the thiazolidinedione class: a focus on safety. Diabetes Metab Res Rev 2002, 18(Suppl 2):S23-S29.
238. Stine J.G., Lewis J.H. Hepatotoxicity of antibiotics: a review and update for the clinician. Clin Liver Dis 2013, 17:609-642.
239. Hawton K., Bergen H., Simkin S., et al. Impact of different pack sizes of paracetamol in the United Kingdom and Ireland on intentional overdoses: a comparative study. BMC Public Health 2011, 11:460.
240. Hawton K., Bergen H., Simkin S., et al. Long term effect of reduced pack sizes of paracetamol on poisoning deaths and liver transplant activity in England and Wales: interrupted time series analyses. BMJ 2013, 346:f403.
241. King J.P., Davis T.C., Bailey S.C., et al. Developing consumer-centered, nonprescription drug labeling a study in acetaminophen. Am J Prev Med 2011, 40:593-598.
242. Bari K., Fontana R.J. Acetaminophen overdose: what practitioners need to know. Clinical Liver Dis 2014, 4:17-21.
243. Wree A., Dechene A., Herzer K., et al. Steroid and ursodesoxycholic acid combination therapy in severe drug-induced liver injury. Digestion 2011, 84:54-59.
244. Rumack B.H., Bateman D.N. Acetaminophen and acetylcysteine dose and duration: past, present and future. Clin Toxicol (Phila) 2012, 50:91-98.
245. Green J.L., Heard K.J., Reynolds K.M., et al. Oral and intravenous acetylcysteine for treatment of acetaminophen toxicity: a systematic review and meta-analysis. West J Emerg Med 2013, 14:218-226.
246. Schmidt L.E. Identification of patients at risk of anaphylactoid reactions to N-acetylcysteine in the treatment of paracetamol overdose. Clin Toxicol (Phila) 2013, 51:467-472.
247. Russell S. Carnitine as an antidote for acute valproate toxicity in children. Curr Opin Pediatr 2007, 19:206-210.
248. Shea B., Swinden M.V., Ghogomu M.T., et al. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. J Rheumatol 2014, 41:1049-1060.
249. Leflunamide. FDA prescribing information. Available at:. Accessed July 18, 2015. http://www.fda.gov/downloads/safety/MedWatch/Safetyinformation/safetyalertsforhumanmedicalproducts/ucm168409.pdf.
250. Banares R., Catalina M.V., Vaquero J. Molecular adsorbent recirculating system and bioartificial devices for liver failure. Clin Liver Dis 2014, 18:945-956.
251. Saliba F., Camus C., Durand F., et al. Albumin dialysis with a noncell artificial liver support device in patients with acute liver failure: a randomized, controlled trial. Ann Intern Med 2013, 159:522-531.
252. Saliba F., Samuel D. Artificial liver support: a real step forward. Minerva Med 2015, 106:35-43.
253. Abenavoli L., Capasso R., Milic N., et al. Milk thistle in liver diseases: past, present, future. Phytother Res 2010, 24:1423-1432.
254. Mindikoglu A.L., Magder L.S., Regev A. Outcome of liver transplantation for drug-induced acute liver failure in the United States: analysis of the United Network for Organ Sharing database. Liver Transpl 2009, 15:719-729.